| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥5.9B | ¥7.8B | -24.0% |
| Operating Income | ¥-9.8B | ¥-10.3B | +5.0% |
| Ordinary Income | ¥-9.9B | ¥-10.2B | +2.9% |
| Net Income | ¥-9.8B | ¥-10.2B | +3.7% |
| ROE | -87.5% | -53.1% | - |
The first quarter results for FY2025 show revenue of 5.9B yen (down 24.0% YoY) and operating loss of 9.8B yen (loss narrowed 5.0% YoY from prior year loss of 10.3B yen). Ordinary loss was 9.9B yen (improved 2.9% from prior year loss of 10.2B yen) and net loss was 9.8B yen (improved 3.7% from prior year loss of 10.2B yen). While the company maintained a high gross profit margin of 60.0%, selling, general and administrative expenses of 13.4B yen significantly exceeded revenue, resulting in continued operating losses. Total assets declined to 17.3B yen from 24.7B yen, and total equity decreased to 11.2B yen from 19.2B yen, reflecting accumulated losses and cash consumption.
Revenue decreased 24.0% YoY to 5.9B yen, with the Drug Discovery Support segment generating 593 million yen and the Drug Discovery and Development segment contributing 203 million yen. Despite the revenue decline, gross profit margin remained robust at 60.0%, indicating pricing power and technological value retention at the product level. However, SG&A expenses of 13.4B yen represented 225% of revenue, creating substantial operating losses. The expense structure includes R&D investment of 7.8B yen, demonstrating the company's continued commitment to pipeline development despite revenue pressures. The gap between ordinary loss (9.9B yen) and net loss (9.8B yen) was minimal at approximately 100 million yen, indicating limited impact from extraordinary items. Non-operating expenses of 120 million yen exceeded non-operating income of 30 million yen by 90 million yen, but this differential had marginal effect on overall performance given the scale of operating losses. The fundamental challenge stems from fixed cost absorption, where declining revenue volumes cannot support the substantial investment required for drug discovery operations. This represents a revenue down, profit up pattern, as the operating loss narrowed from 10.3B yen to 9.8B yen despite lower sales.
The Drug Discovery Support segment generated revenue of 593 million yen with operating income of 356 million yen, achieving an operating margin of 60.0%. This segment represents the core profitable business with positive cash contribution. The Drug Discovery and Development segment recorded revenue of 203 million yen with operating loss of 777 million yen, resulting in a negative margin of 382.8%. The substantial loss in this segment reflects the investment-intensive nature of drug development activities. The 933 million yen gap between total segment operating profit (negative 421 million yen) and company-wide operating loss (9.8B yen) consists of corporate expenses including administrative functions and research departments outside reportable segments, totaling approximately 9.4B yen. The Drug Discovery Support business serves as the cash-generating core, while Drug Discovery and Development represents the growth investment area with significant capital requirements.
[Profitability] ROE was negative 87.5% due to net loss relative to equity base of 11.2B yen, representing severe deterioration from already weak prior year levels. Operating margin was negative 165.1%, reflecting operating loss of 9.8B yen against revenue of 5.9B yen, compared to negative 132.1% in the prior year. Gross profit margin of 60.0% remained stable despite revenue pressures, indicating retention of core technical value. [Cash Quality] Cash and deposits stood at 12.1B yen, providing short-term debt coverage of 13.9 times against short-term borrowings of 870 million yen. Operating cash flow to net income ratio was 0.95, showing alignment between accounting losses and cash consumption. [Investment Efficiency] Total asset turnover was 0.34, declining from 0.32 in the prior year due to revenue contraction outpacing asset reduction. [Financial Health] Equity ratio decreased to 64.8% from 77.8%, as retained earnings deteriorated to negative 20.0B yen from negative 10.2B yen. Current ratio stood at 412.6%, and quick ratio at 399.4%, both indicating strong short-term liquidity. Debt-to-equity ratio was 0.08, reflecting minimal leverage with interest-bearing debt of 870 million yen.
Operating cash flow of negative 9.4B yen represented 0.95 times net loss of 9.8B yen, confirming that accounting losses translate directly into cash consumption. The operating cash outflow was driven primarily by the operating loss of 9.8B yen, partially offset by working capital adjustments. Investing cash flow of negative 550 million yen consisted mainly of capital expenditures of 400 million yen, representing 10.7 times depreciation of 40 million yen, indicating strategic facility investment despite operational challenges. Free cash flow of negative 9.9B yen reflects the combination of operating cash consumption and continued investment activities. Cash and deposits decreased by 8.6B yen from 20.6B yen to 12.1B yen, representing a 41.6% reduction that corresponds to the negative free cash flow and any financing activities. The cash burn rate of approximately 9.9B yen annually suggests current cash reserves could support operations for approximately 1.2 years at the current run rate, absent additional financing or operational improvements.
Ordinary loss of 9.9B yen versus operating loss of 9.8B yen shows non-operating net expense of approximately 100 million yen, representing minimal impact relative to the scale of operations. Non-operating income of 30 million yen and non-operating expenses of 120 million yen resulted in net non-operating expense of 90 million yen, comprising primarily interest expenses and other financial costs. Non-operating items represent 1.5% of revenue, indicating limited reliance on non-core income sources. The alignment between operating loss and ordinary loss confirms that earnings quality issues stem from core operations rather than financial engineering or one-time items. Operating cash flow exceeds net income in absolute terms (negative 9.4B yen versus negative 9.8B yen), with the 0.95 ratio indicating minimal accrual-based distortions. The earnings quality reflects genuine operational challenges rather than accounting manipulations, with cash conversion metrics confirming that reported losses accurately represent economic reality.
Annual dividend per share is zero for the full year forecast, with no interim or year-end distributions planned. No dividend was paid in the prior year, continuing the suspension of shareholder returns. Given the net loss of 9.8B yen, payout ratio is not applicable. No share buyback activities were disclosed. The total return ratio to shareholders is zero as neither dividends nor buybacks are being executed. The absence of shareholder returns aligns with the company's financial position, characterized by operating losses, negative retained earnings of 20.0B yen, and ongoing cash consumption of 9.9B yen in free cash flow. Dividend resumption would require substantial improvement in profitability and cash generation.
Pipeline development risk represents the primary concern, as the Drug Discovery and Development segment recorded operating losses of 777 million yen on revenue of only 203 million yen, indicating that clinical trial failures or regulatory delays could eliminate potential revenue streams without reducing the fixed cost base. Current R&D expenses of 7.8B yen represent 132% of total revenue, creating significant financial vulnerability if development programs fail to advance.
Cash depletion risk has materialized with cash and deposits declining 41.6% from 20.6B yen to 12.1B yen year-over-year, driven by operating cash outflow of 9.4B yen. At the current burn rate of approximately 9.9B yen annually in free cash flow, existing cash reserves of 12.1B yen provide roughly 1.2 years of runway, necessitating either operational breakeven, revenue growth, or external financing within this timeframe.
Short-term liability concentration presents refinancing risk, as 100% of interest-bearing debt consists of short-term borrowings of 870 million yen. While the absolute amount is modest relative to cash holdings, the deterioration in retained earnings to negative 20.0B yen and equity decline from 19.2B yen to 11.2B yen may constrain future borrowing capacity or worsen refinancing terms when needed.
[Industry Position] (Reference - Proprietary Analysis). The company's operating margin of negative 165.1% falls substantially below typical pharmaceutical and biotechnology industry standards, reflecting its pre-revenue or early-stage development profile where R&D investment precedes commercialization. The ROE of negative 87.5% contrasts sharply with established pharmaceutical companies that typically maintain positive mid-to-high single digit ROE levels. The equity ratio of 64.8% remains relatively healthy compared to highly leveraged biotech ventures, indicating conservative capital structure despite operational losses. Based on historical trend data, the company has experienced persistent negative profitability with operating margins remaining deeply negative at 165.1% in 2025, and revenue declining 24.0% year-over-year. This positioning is characteristic of early-stage drug discovery companies where value creation depends on pipeline advancement rather than current profitability metrics. The financial profile suggests the company operates in the high-risk, high-potential-return segment of the pharmaceutical industry, where success depends on clinical milestones and partnership agreements rather than immediate earnings generation.
The financial profile reveals a company in active drug discovery investment phase, consuming approximately 9.9B yen annually in free cash flow while maintaining 12.1B yen in cash reserves, implying a critical 12-to-18-month window for achieving operational milestones or securing additional financing. The Drug Discovery Support segment demonstrates profitable unit economics with 60.0% operating margin, providing a foundation of cash-generating capability, while the Drug Discovery and Development segment operates at negative 383% margin, reflecting the capital-intensive nature of pipeline advancement.
The structural challenge of SG&A expenses representing 225% of revenue creates urgent need for either revenue expansion or cost rationalization, with R&D spending of 7.8B yen constituting the largest controllable expense component that must be balanced against pipeline value creation. The 41.6% year-over-year decline in cash reserves from 20.6B yen to 12.1B yen establishes a clear timeline for value inflection events such as clinical trial results, licensing agreements, or partnership announcements that could alter the financial trajectory.
The equity base erosion from 19.2B yen to 11.2B yen and retained earnings deterioration to negative 20.0B yen indicate that future equity financing would occur at increasingly dilutive terms absent positive clinical or commercial developments, creating pressure for near-term operational improvements or strategic transactions.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.